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Abstract
Bone marrow fibrosis is a hallmark of primary and post ET/PV myelofibrosis. To investigated the impact of
replacement of the hematopoietic system in myelofibrosis patients by allogeneic stem cell transplantation on bone
marrow fibrosis, we studied bone marrow fibrosis on bone marrow samples from 24 patients with myelofibrosis
before and after dose-reduced conditioning followed by allogeneic stem cell transplantation from related or
unrelated donor. Using the European Consensus on Grading Bone Marrow Fibrosis, before allografting all patients
had advanced fibrosis MF-2 (n = 13) or MF-3 (n = 11). After transplantation, a complete (MF-0) or nearly complete
(MF-1) regression of bone marrow fibrosis was seen in 59 % at day +100, in 90 % at day +180, and in 100 % at
day +360. No correlation between occurrence of acute graft-versus-host disease, and fibrosis regression on day
+180 was seen. We conclude that dose-reduced conditioning, followed by allogeneic stem cell transplantation,
resulted in a rapid resolution of bone-marrow fibrosis suggesting the bone marrow fibrogenesis is a highly
dynamic rather than static process in patients with myelofibrosis.
Introduction
Myelofibrosis with myeloid metaplasia (MMM) is a rare
malignant hematological disease of the hematopoietic
stem cells with a median age at diagnosis of 60 years.
Myelofibrosis is characterized by splenomegaly, extrame-
dullary hematopoiesis, bone marrow collagen fibrosis,
and osteosclerosis [1]. Bone marrow fibroblasts in
patients with myelofibrosis are polyclonal and exhibit
normal function [2]. Clinical and preclinical observation
suggested that cellular and extracellular levels of fibro-
genic and angiogenic cytokines are altered in patients
with myelofibrosis Conventional therapy is mainly used
to control symptoms whereas no such therapy has so far
shown to change the natural course of the disease. The
only curative treatment option is hematopoietic stem cell
transplantation [3]. With allogeneic stem cell transplan-
tation, about 50 % of the patients can be cured from their
d i s e a s eb u tt h ee f f e c to nb o n em a r r o wf i b r o s i sh a sn o t
been investigated systematically so far. Therefore we
evaluated bone-marrow-fibrosis regression in patients
with myelofibrosis after dose-reduced conditioning
(busulfan, 10 mg/kg BW; fludarabine, 180 mg/m²; and
ATG, 30 - 60 mg/kg BW), followed by allogeneic stem
cell transplantation from related (n = 6) or un-related
(n = 18) donor.
Methods and patients
Twenty-four patients (male: n = 16; female: n = 8) with
a median age of 52 years (range, 32-63) were included.
T h e r ew e r e1 6m a l ea n d8f e m a l ep a t i e n t s .D i a g n o s i s
was primary myelofibrosis in 18 patients and secondary
myelofibrosis in six patients; four of them developed
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sensus on Grading [4]. This consensus distinguishes
between:
MF - 0 Scattered linear reticulin with no intersections
[cross-overs] corresponding to normal bone marrow
MF - 1 Loose network of reticulin with many intersec-
tions, especially in paravascular areas
MF - 2 Diffuse and dense increase in reticulin with
extensive intersections, occasionally with only focal bun-
dles of collagen and/or focal osteosclerosis
MF - 3 Diffuse and dense increase in reticulin with
extensive intersections with coarse bundles of collagen,
often associated with significant osteosclerosis
Fibrosis grading was determined independently by two
experienced hemato-pathologists.
All patients underwent bone marrow biopsy prior allo-
geneic stem cell transplantation. A first biopsy after trans-
plantation should be performed between day +30 and day
+100, a second bone marrow histology on day +180, and a
third histology one year after transplantation. Patients
could be included if they had at least one bone marrow
histology within the first 180 days after transplantation.
The study was approved by the ethic committee of
Hamburg/Germany. All patients gave written informed
consent for participation in the study.
Results
From all patients, bone marrow histology was obtained
before allogeneic stem cell transplantation (n = 24).
After transplantation, 76 bone marrow histologies were
performed. Bone Marrow Fibrosis, before allografting all
patients had advanced fibrosis MF-2 (n = 13) or MF-3
(n = 11). After transplantation, a complete (MF-0) or
nearly complete (MF-1) regression of bone marrow
fibrosis was seen in 59 % at day +100, in 90 % at day
+180, and in 100 % at day +360. (see table 1). No corre-
lation between occurrence of acute graft-versus-host dis-
ease, and fibrosis regression on day +180 was seen.
Discussion
The pathogenesis of bone marrow fibrosis is not com-
pletely understood. A pathogenic role for developing
Table 1
Grade* n = 24 n = 22 n= 20 n = 16
prior allograft day +30 to day +100 day +180 day +360
3 11 (49 %) 2 (9 %) 0 0
2 13 (51 %) 7 (32 %) 2 (10 %) 0
1 0 9 (41 %)) 9 (45 %) 6 (37 %)
0 0 4 (18 %) 9 (45 %) 10 (63 %)
*according to the European Consensus on Grading Bone Marrow Fibrosis
Figure 1 Representative example of bone marrow regression in a patient after dose-reduced allografting on day +30 and +100.
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growth-factor beta (TGF-b), platelet-derived-growth fac-
tor (PDGF), basis-fibroblast-growth factor (BFGF), and
vascular-endothelial-growth factor (VEGF) [2,5,6].
Furthermore also the interactions between cytokine
release, myeloid stoma and other bone-marrow cells are
only partially understood. Megakaryocytes are suggested
to play a major role as source of cytokine release [6,7].
Furthermore, pathologic interaction between megakar-
yocytes and neutrophiles (emperipolesis) contributes to
abnormal cytokine release [8]. Although the bone mar-
row texture is distored by fibrosis, donor-stem cells can
engraft after a reduced intensity conditioning without
obvious delay, suggesting that the bone marrow milieu
for stem cell homing is apparently not seriously altered.
It sounds reasonable that replacement of abnormal clo-
nal hematopoietic cell population by allogeneic stem cell
transplantation would eliminate the stimulus for abnor-
mal cytokine release. Indeed several reports of allogeneic
stem cell transplantation after standard conditioning for
myelofibrosis reported a reversal of bone marrow fibro-
sis between six and 12 months after transplantation
[9,10]. Since reduced intensity conditioning followed by
allogeneic stem cell transplantation is becoming a rea-
sonable treatment option for elder patients with inter-
mediate or high-risk myelofibrosis [3], we systematically
investigated the kinetics and dynamics of fibrosis regres-
sion in bone marrow after dose-reduced conditioning
followed by allogeneic stem cell transplantation. Surpris-
ingly, more than 59 % of the patients achieved complete
or nearly complete regression of fibrosis (MF-1 and MF-
0 shortly after engraftment at day +30; this percentage
increased to 90 % at day +180, and to 100 % after one
year. This rapid regression of bone marrow fibrosis sug-
gests that fibrogenesis in myelofibrosis patients is a
rather dynamic than static process.
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